NASDAQ · PRQR
ProQR Therapeutics N.V financials
$1.650.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 | Q4 '17 Dec 31 | Q4 '16 Dec 31 | Q4 '15 Dec 31 | Q4 '14 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted shares | 105.3M | 86.1M | 81.0M | 71.6M | 64.2M | 50.1M | 41.0M | 34.1M | 25.4M | 23.3M | 23.3M | 11.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $108.4M | $155.5M | $131.5M | $94.8M | $213.2M | $92.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.7M | $4.8M | $4.7M | $6.8M | $50.1M | $21.1M |
| Total assets | $132.3M | $174.8M | $152.4M | $171.3M | $238.3M | $120.2M |
| Total liabilities | $74.4M | $82.6M | $106.7M | $104.6M | $109.6M | $51.4M |
| Shareholders' equity | $57.9M | $92.2M | $45.8M | $66.7M | $128.8M | $68.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology